Abstract
As the fastest growing class of therapeutic proteins, monoclonal antibodies (mAbs) represent a major potential drug class1. Human antibodies are glycosylated in their native state and all clinically approved mAbs are produced by mammalian cell lines, which secrete mAbs with glycosylation structures that are similar, but not identical, to their human counterparts. Glycosylation of mAbs influences their interaction with immune effector cells that kill antibody-targeted cells2,3,4,5,6. Here we demonstrate that human antibodies with specific human N-glycan structures can be produced in glycoengineered lines of the yeast Pichia pastoris and that antibody-mediated effector functions can be optimized by generating specific glycoforms. Glycoengineered P. pastoris provides a general platform for producing recombinant antibodies with human N-glycosylation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Weiner, L.M. & Carter, P. Tunable antibodies. Nat. Biotechnol. 23, 556–557 (2005).
Rothman, R.J., Perussia, B., Herlyn, D. & Warren, L. Antibody-dependent cytotoxicity mediated by natural killer cells is enhanced by castanospermine-induced alterations of IgG glycosylation. Mol. Immunol. 26, 1113–1123 (1989).
Lifely, M.R., Hale, C., Boyce, S., Keen, M.J. & Phillips, J. Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Glycobiology 5, 813–822 (1995).
Umaña, P. et al. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. 17, 176–180 (1999).
Shields, R.L. et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277, 26733–26740 (2002).
Shinkawa, T. et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytoxicity. J. Biol. Chem. 278, 3466–3473 (2003).
Clynes, R.A., Towers, T.L., Presta, L.G. & Ravetch, J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6, 443–446 (2000).
Cartron, G. et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99, 754–758 (2002).
Choi, B.-K. et al. Use of combinatorial genetic libraries to humanized N-linked glycosylation in the yeast Pichia pastoris. Proc. Natl. Acad. Sci. USA 100, 5022–5027 (2003).
Hamilton, S. et al. Production of complex human glycoproteins in yeast. Science 301, 1244–1246 (2003).
Bobrowicz, P. et al. Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast Pichia pastoris: Production of complex humanized glycoproteins with terminal galactose. Glycobiology 14, 757–766 (2004).
Gerngross, T.U. Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nat. Biotechnol. 22, 1409–1414 (2004).
Wright, A. et al. In vivo trafficking and catabolism of IgG1 with Fc associated carbohydrates of differing structure. Glycobiology 10, 1347–1355 (2000).
Wright, A. & Morrison, S.L. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. J. Immunol. 160, 3393–3402 (1998).
Anderson, D.R. et al. Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma. US Patent No. 6,682,734 (1995).
Hong, K. et al. Simple quantitative live cell and anti-idiotypic antibody based ELISA for humanized antibody directed to cell surface protein CD20. J. Immunol. Methods 294, 189–197 (2004).
Shields, R.L. et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII and FcRn and design of IgG1 variants with improved binding to the FcgR. J. Biol. Chem. 276, 6591–6604 (2001).
Vugmeyster, Y. & Howell, K. Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: possible inhibitory effect of IgG. Int. Immunopharmacol. 4, 1117–1124 (2004).
Acknowledgements
We wish to acknowledge Ron Hitzman and Max Vasquez for their continued input on improving antibody expression and quality. Erin Giaccone, Sujatha Gomathinayagam, Heather Lynaugh, Teresa Mitchell and Alissa Thompson are acknowledged for excellent technical assistance and Jim Posada is acknowledged for his insistence on developing a yeast-based antibody expression platform.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
All authors, with the exception of T.U.G., J.P.H. and R.S., who hold faculty positions at Dartmouth College, are employess of GlycoFi. All authors, excluding J.P.H. and R.S., have a financial interest in the company.
Supplementary information
Supplementary Fig. 1
Plasmid construct pDX478 used for the expression of rituximab in P. pastoris. (PDF 211 kb)
Rights and permissions
About this article
Cite this article
Li, H., Sethuraman, N., Stadheim, T. et al. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat Biotechnol 24, 210–215 (2006). https://doi.org/10.1038/nbt1178
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1178
This article is cited by
-
Effect of Fc core fucosylation and light chain isotype on IgG1 flexibility
Communications Biology (2023)
-
From strain engineering to process development: monoclonal antibody production with an unnatural amino acid in Pichia pastoris
Microbial Cell Factories (2022)
-
Mechanism of cooperative N-glycan processing by the multi-modular endoglycosidase EndoE
Nature Communications (2022)
-
Design of a novel switchable antibody display system in Pichia pastoris
Applied Microbiology and Biotechnology (2022)
-
Developing a medium combination to attain similar glycosylation profile to originator by DoE and cluster analysis method
Scientific Reports (2021)